Inhibition of IL-6 for the treatment of inflammatory diseases.
Interleukin-6 (IL-6) is a pleiotropic cytokine with various biological activities. Deregulated overproduction of IL-6 has been found to play pathological roles in chronic inflammatory diseases such as rheumatoid arthritis, Castleman's disease, juvenile idiopathic arthritis and Crohn's disease. Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies.
Nishimoto
Norihiro
N
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita-City, Osaka, 565-0871, Japan. norihiro@fbs.osaka-u.ac.jp
Kishimoto
Tadamitsu
T
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy; D005871:Castleman Disease / Q000628:therapy; D003424:Crohn Disease / Q000628:therapy; D006801:Humans; D007249:Inflammation / Q000628:therapy*; D015850:Interleukin-6 / Q000502:physiology; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors; D016706:Still's Disease, Adult-Onset / Q000628:therapy; D000093242:Interleukin-6 Inhibitors
D000906:Antibodies; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D000093242:Interleukin-6 Inhibitors